The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Jan. 24, 1:07 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #51. Jazz Pharmaceuticals plc Gentium S.p.A.

Acquirer: Jazz Pharmaceuticals plc (JAZZ)
Acquiree: Gentium S.p.A. (GENT)
Details: Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A. (Nasdaq: GENT) today announced that they have entered into a definitive agreement pursuant to which a subsidiary of Jazz Pharmaceuticals will make a cash tender offer of $57.00 per share for all outstanding Gentium ordinary shares and American Depositary Shares, in a transaction that is valued at approximately $1 billion.

Jazz Pharmaceuticals is a biopharmaceutical company. Co.'s products are: Xyrem®, which is for the treatment of both cataplexy and excessive daytime sleepiness (EDS), in both adult and pediatric patients with narcolepsy; Sunosi®, which improves wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea; Defitelio®, which treats adult and pediatric patients with hepatic veno-occlusive disease; Erwinaze®, which is a treatment for patients with acute lymphoblastic leukemia; and Vyxeos®, which is a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.

JAZZ SEC Filing Email Alerts Service


Open the JAZZ Page at The Online Investor »

Jazz Pharmaceuticals is a biopharmaceutical company. Co.'s products are: Xyrem®, which is for the treatment of both cataplexy and excessive daytime sleepiness (EDS), in both adult and pediatric patients with narcolepsy; Sunosi®, which improves wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea; Defitelio®, which treats adult and pediatric patients with hepatic veno-occlusive disease; Erwinaze®, which is a treatment for patients with acute lymphoblastic leukemia; and Vyxeos®, which is a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.

JAZZ SEC Filing Email Alerts Service


Open the GENT Page at The Online Investor »

Company Name: 
Jazz Pharmaceuticals Plc
Stock buyback: 
JAZZ buyback
Website: 
www.jazzpharmaceuticals.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding JAZZ: 
82
Total Market Value Held by ETFs: 
$1.31B
Total Market Capitalization: 
$8.64B
% of Market Cap. Held by ETFs: 
15.17%
Company Name: 
Gentium SpA
Website: 
www.gentium.it
Sector: 
Biotechnology
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 51 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.